BioSpace News Archive

CVD Equipment Corporation (NASDAQ: CVV), a leading provider of chemical vapor deposition systems and materials, today announced its second quarter 2019 financial results.

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the commencement of a registered underwritten public offering of $200.0 million in shares of its common stock.

Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, announced today its reported results for the second quarter ended June 30, 2019.

Medicine Man Technologies, Inc. (OTCQX: MDCL) (“Medicine Man Technologies” or “Company”), today announced that the Company will host a conference call to discuss operational and financial highlights from its second quarter 2019 on Thursday, August 15, 2019 at 4:15 p.m. ET.

Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the closing of its previously announced underwritten public offering of 2,732,673 shares of its common stock at a public offering price of $25.25 per share, including 356,435 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares

Fuse Medical, Inc. announced that it has filed its quarterly report on Form 10-Q for the second quarter ended June 30, 2019, with the United States Securities and Exchange Commission, on Monday, August 12, 2019.

Ironwood Pharmaceuticals, Inc. announced that, in connection with its previously announced offering of 0.75% Convertible Senior Notes due 2024 and 1.50% Convertible Senior Notes due 2026, the initial purchaser exercised in full its option to purchase $25 million aggregate principal amount of the 2024 Notes and $25 million aggregate principal amount of the 2026 Notes.

Portola Pharmaceuticals, Inc. announced the pricing of its underwritten public offering of 8,035,715 shares of its common stock at a price to the public of $28.00 per share.

Executives with experience from Kraft, P&G, Leo Burnett, LanzaTech and Cargill join alternative protein company’s Board of Directors and leadership team

Transaction Creates Expanded Portfolio of Cloud-Based Capabilities to Advance Clinical Development